NCT03992261View on ClinicalTrials.gov

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2019

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions

Plaque Psoriasis

Interventions

DRUG

Halobetasol Topical Foam

Foam

Trial Locations (11)

33012

Investigative Site 2, Hialeah

64506

Investigative Site 1, Saint Joseph

Unknown

Investigative Site 9, Batumi

Investigative Site 3, Krakow

Investigative Site 5, Tarnów

Investigative Site 4, Warsaw

Investigative Site 8, Rivne

Investigative Site 6, Uzhhorod

Investigative Site 7, Zaporizhzhya

0114

Investigative Site 10, Tbilisi

0177

Investigative Site 11, Tbilisi

All Listed Sponsors

lead

Mayne Pharma International Pty Ltd

INDUSTRY

NCT03992261 - Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis | Biotech Hunter | Biotech Hunter